论文部分内容阅读
狂犬病是100%致死的疾病,但可用疫苗和免疫球蛋白进行预防。作者开发了Vero细胞狂犬病疫苗(Rabivax-S)并通过肌内(IM)和皮内(ID)途径接种评价了它的安全性和免疫原性。这是180名(5岁及以上)疑似狂犬病暴露者(WHO II类和III类各90人暴露)参与的随机非劣性对照研究。参与者或者接种Rabivax-S(1 mL IM;5剂),Rabivax-S(ID为0.1 mL;8剂量)或接种纯化
Rabies is a 100% lethal disease but can be prevented with vaccines and immunoglobulins. The authors developed the Vero cell rabies vaccine (Rabivax-S) and evaluated its safety and immunogenicity by intramuscular (IM) and intradermal (ID) route inoculation. This is a randomized non-inferiority controlled trial of 180 suspected (5 years and older) rabies-exposed individuals (WHO 90 and 90 exposed). Participants were either vaccinated with Rabivax-S (1 mL IM; 5 doses), Rabivax-S (ID 0.1 mL; 8 doses) or seeded